SCHEMBL6484092

SCHEMBL6484092

Cc1cc(Cc2ccc(F)cc2)c(=O)n2nc(C#Cc3ccccc3)oc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
FPR1 P21462 4/20 0.35
CNR2 P34972 2/20 0.33
GPR55 Q9Y2T6 2/20 0.33
MAPK14 Q16539 1/20 0.33
GRM4 Q14833 4/20 0.33
CNR1 P21554 1/20 0.32
FPR2 P25090 2/20 0.32
MAPT P10636 3/20 0.32
RET P07949 1/20 0.32
KDR P35968 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32
TSHR P16473 1/20 0.32
MMP13 P45452 1/20 0.32
MMP2 P08253 1/20 0.31
MMP9 P14780 1/20 0.31
MMP12 P39900 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6814248 0.91 MEN1 (0.33) MEN1KMT2AFPR1GRM4
SCHEMBL6490898 0.88 TSHR (0.37) MEN1KMT2AFPR1FPR2TSHR
SCHEMBL6475676 0.78 MEN1 (0.39) MEN1KMT2AFPR1MAPK14GRM4
SCHEMBL6476602 0.78 FPR1 (0.44) MEN1KMT2AFPR1CNR2GPR55
SCHEMBL6475923 0.75 MAPT (0.46) MEN1KMT2AMAPTTSHRKDM4E
SCHEMBL6489420 0.71 GRM4 (0.35) GRM4
SCHEMBL6477198 0.69 TSHR (0.38) MEN1KMT2AFPR1PDE3BPDE3A
SCHEMBL6484773 0.67 MEN1 (0.41) MEN1KMT2AFPR1CNR2GPR55
SCHEMBL6488680 0.67 TSHR (0.38) MEN1KMT2AFPR1FPR2MAPT
SCHEMBL6485436 0.66 CNR2 (0.40) MEN1KMT2AFPR1CNR2GPR55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6897223-B2 Pyridine fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-05-24 US disclosed
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors WILSON MICHAEL WILLIAM (US) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 MEN1 3457/4885KMT2A 2335/4885FPR1 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.